Log in or Sign up for Free to view tailored content for your specialty!
Liver/Biliary Disorders News
Up-to-date HCC screening after HCV cure improves survival in patients with cirrhosis
Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.
Risk for heart, liver disease may vary between PCOS subtypes
Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.
Log in or Sign up for Free to view tailored content for your specialty!
Fazirsiran lowers serum, liver concentrations of Z-AAT in alpha-1 antitrypsin deficiency
In a dose-dependent manner, fazirsiran reduced serum and liver concentrations of Z-AAT and also improved histological measures in patients with homozygous ZZ alpha-1 antitrypsin deficiency-associated liver disease, according to data.
‘Even one meal change’ to vegetarian, vegan can reduce serum ammonia in cirrhosis
Substitution of just one meat-based meal with a vegetarian or vegan alternative reduced serum ammonia levels for up to 3 hours and improved metabolites in patients with cirrhosis who follow a Western meat-based diet, researchers reported.
VIDEO: GLP-1 use for MASH is ‘not black and white’; best approach may lie in the gray
In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that, despite the boom in glucagon-like peptide-1 agonists for diabetes and weight loss, its role in the treatment of liver disease is still up for debate.
‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH
Metabolic dysfunction-associated steatotic liver disease affects more than one-third of the world’s population and is associated with significant clinical and economic burden, as well as impairment of health-related quality of life.
‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH
To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.
More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes
Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.
‘Future of treating MASH’ will combine GLP-1 drugs, liver-specific medications
Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally. The prevalence has risen in parallel with epidemics of obesity and type 2 diabetes.
Manage lifestyle early and aggressively to prevent, instead of treat, fatty liver
Millions of dollars have been spent trying to find medications that could treat this complex disorder. The focus has been on drugs for more severe disease, as it leads to complications, and early stages have been somewhat ignored.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read